{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:57Z","timestamp":1793386797816,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.healun.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T23:02:47Z","timestamp":1653001367000},"page":"1258-1267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5609-3937","authenticated-orcid":false,"given":"Bradley J.","family":"Gardiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-5308","authenticated-orcid":false,"given":"Allisa N.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory I.","family":"Snell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Orla","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-2126","authenticated-orcid":false,"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen P.","family":"Westall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2022.05.004_bib0001","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","article-title":"Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2022.05.004_bib0002","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/528689","article-title":"Ganciclovir\/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation","volume":"46","author":"Chmiel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0003","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1164\/rccm.200310-1405OC","article-title":"Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome","volume":"170","author":"Tamm","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2022.05.004_bib0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-5223(97)70144-2","article-title":"Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation","volume":"114","author":"Kroshus","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.healun.2022.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/ajrccm\/146.6.1419","article-title":"Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients","volume":"146","author":"Duncan","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.healun.2020.10.009","article-title":"Risk factors for mortality in lung transplant recipients aged \u226565 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients","volume":"40","author":"Mosher","year":"2021","journal-title":"J HeartLung Transpl"},{"key":"10.1016\/j.healun.2022.05.004_bib0007","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0008","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.healun.2022.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.TP.0000145989.22373.03","article-title":"Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis","volume":"78","author":"Limaye","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.05.004_bib0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.healun.2004.02.005","article-title":"Extended ganciclovir prophylaxis in lung transplantation","volume":"24","author":"Perreas","year":"2005","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2022.05.004_bib0011","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/TP.0b013e3181ea3955","article-title":"An international survey of cytomegalovirus management practices in lung transplantation","volume":"90","author":"Zuk","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.05.004_bib0012","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.05.004_bib0013","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11908-018-0610-4","article-title":"Immune monitoring for CMV in transplantation","volume":"20","author":"Yong","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.healun.2022.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/lt.24216","article-title":"Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation","volume":"21","author":"Sood","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2022.05.004_bib0016","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0017","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1600-6143.2008.02294.x","article-title":"Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity","volume":"8","author":"Westall","year":"2008","journal-title":"Am J Transpl"},{"key":"10.1016\/j.healun.2022.05.004_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/erm.10.109","article-title":"QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity","volume":"11","author":"Giulieri","year":"2011","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.healun.2022.05.004_bib0019","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0020","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/ajt.15793","article-title":"Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-gamma release assay in kidney transplant recipients treated with antithymocyte globulin","volume":"20","author":"Fernandez-Ruiz","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0021","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.05.004_bib0022","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","article-title":"Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection","volume":"26","author":"Stewart","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0023","unstructured":"Genentech: Valcyte (valganciclovir), package insert. 2015."},{"key":"10.1016\/j.healun.2022.05.004_bib0024","unstructured":"Genentech: Cytovene (ganciclovir), package insert. 2016."},{"key":"10.1016\/j.healun.2022.05.004_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ctr.12686","article-title":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis","volume":"30","author":"Beam","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0026","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.healun.2011.02.017","article-title":"Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial","volume":"30","author":"Finlen Copeland","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0027","doi-asserted-by":"crossref","first-page":"e13277","DOI":"10.1111\/tid.13277","article-title":"Extending cytomegalovirus prophylaxis in high-risk (D+\/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: a retrospective study","volume":"22","author":"Herrera","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0028","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.healun.2009.03.012","article-title":"Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy","volume":"28","author":"Jaksch","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0029","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial","volume":"152","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2022.05.004_bib0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1600-6143.2011.03837.x","article-title":"Is prevention the best treatment? CMV after lung transplantation","volume":"12","author":"Patel","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0031","doi-asserted-by":"crossref","first-page":"e13138","DOI":"10.1111\/tid.13138","article-title":"Indefinite cytomegalovirus prophylaxis with valganciclovir after lung transplantation","volume":"21","author":"Hecker","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1399-3062.2012.00723.x","article-title":"Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis","volume":"14","author":"Wiita","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0033","doi-asserted-by":"crossref","first-page":"e13069","DOI":"10.1111\/tid.13069","article-title":"Cytomegalovirus viremia in lung transplantation during and after prophylaxis","volume":"21","author":"Chang","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0034","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.pathol.2018.04.002","article-title":"Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia","volume":"50","author":"Thompson","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.healun.2022.05.004_bib0035","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/ajt.13781","article-title":"Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants","volume":"16","author":"Kaminski","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0036","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.healun.2010.04.022","article-title":"Cytomegalovirus disease among donor-positive\/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis","volume":"29","author":"Mitsani","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0037","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1600-6143.2009.02574.x","article-title":"A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients","volume":"9","author":"Monforte","year":"2009","journal-title":"Am JTransplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0038","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4081\/mrm.2021.706","article-title":"Efficacy of low-dose valganciclovir in CMV R+ lung transplant recipients: a retrospective comparative analysis","volume":"16","author":"Hunt","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.healun.2022.05.004_bib0039","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.transproceed.2019.11.002","article-title":"Monitoring of CMV-specific cell-mediated immunity in kidney transplant recipients with a high risk of CMV disease (D+\/R-): A Case Series","volume":"52","author":"Andreani","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2022.05.004_bib0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.healun.2020.01.001","article-title":"QuantiFERON-CMV guided virostatic prophylaxis after heart transplantation","volume":"39","author":"Poglajen","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.05.004_bib0041","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0042","doi-asserted-by":"crossref","first-page":"e13550","DOI":"10.1111\/tid.13550","article-title":"Evaluation of Quantiferon(R)-Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients","volume":"23","author":"Gardiner","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2022.05.004_bib0043","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324982201943X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105324982201943X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:46:59Z","timestamp":1760950019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105324982201943X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S105324982201943X"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2022.05.004","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Heart and Lung Transplantation. All rights reserved.","name":"copyright","label":"Copyright"}]}}